RC
Rocket Pharmaceuticals, Inc.
RCKT · NASDAQ
$3.37 -2.88% (-$0.10)
1M -4.53%
Market Cap $382.2M
P/E Ratio -
Div. Yield -
ROE 5.76%
Bulios Fair Price
$2.57
23.7% downside
Current Price
$3.37
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RCKT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
38 /100
Fair P/B 1.04x
EV/EBITDA 22.95x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 17.28%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 4.08%
ROIC 97.05%
Asset turnover 0.00x
Debt
80 /100
Low Int. coverage -0.83x
Debt/Equity 0.07x
Net debt/EBITDA -25.12x
Stability
71 /100
Stable Profitable years 0
Beta 0.50x
EPS volatility 10.52%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RCKT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gaurav D. Shah
Employees
202
Headquarters
Cranbury
Upcoming events
05 NOV
Earnings
Upcoming earnings report